Early Detection Leaders

Cancer Prevention Research & Development

Cancer continues to be one of the world's most urgent unmet medical challenges. Dyne Immune Institute's mission is to create solutions via early detection and treatment of cancer contributing to a healthier society worldwide.

Prevention of cancer is achieved through the early detection of malignant neoplasms. These growths are known to shed protein antigens at concentrations currently beyond the level of detection of existing bioanalytical methods. Dyne Immune has developed bioanalytical methods that can detect these oligopeptide exogenous antigens in the nanomole to attomole range with linear standard curves, by employing photon counting and conjugated specific antibodies. The linear range of the assay is over 10 orders of magnitude with correlation coefficients of 0.97 or greater.

At these levels of concentration cancerous tumors can be detected at extremely low concentration making remediation via chemotherapy and immunotherapy exceedingly successful.

Partner with us if you're interested in collaborating with our team, contact us at partner@dyneimmuneinstitute.com.com to learn more about the work we're pursuing.